Plasma proteins predict conversion to dementia from prodromal disease.
Alzheimer's and Dementia
© 2014 The Authors. Published by Elsevier Inc. on behalf of The Alzheimer’s Association. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
BACKGROUND: The study aimed to validate previously discovered plasma biomarkers associated with AD, using a design based on imaging measures as surrogate for disease severity and assess their prognostic value in predicting conversion to dementia. METHODS: Three multicenter cohorts of cognitively healthy elderly, mild cognitive impairment (MCI), and AD participants with standardized clinical assessments and structural neuroimaging measures were used. Twenty-six candidate proteins were quantified in 1148 subjects using multiplex (xMAP) assays. RESULTS: Sixteen proteins correlated with disease severity and cognitive decline. Strongest associations were in the MCI group with a panel of 10 proteins predicting progression to AD (accuracy 87%, sensitivity 85%, and specificity 88%). CONCLUSIONS: We have identified 10 plasma proteins strongly associated with disease severity and disease progression. Such markers may be useful for patient selection for clinical trials and assessment of patients with predisease subjective memory complaints.
Medical Research Council (MRC)
Alzheimer’s Research UK
The National Institute for Health Research (NIHR) Biomedical Research Centre
Biomedical Research Unit for Dementia
AddNeuroMed through the EU FP6 program
Innovative Medicines Initiative Joint Undertaking under an EMIF grant
European Union’s Seventh Framework Programme (FP7/2007-2013)
Research Support, Non-U.S. Gov't
Alzheimer's and Dementia, 2014, Vol. 10, Issue 6, pp. 799 - 807
Place of publication